SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Thursday, October 29, 2026, at 8:30 a.m. EDT to report its third quarter 2026 financial results.

To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 3074036. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.

About LENZ Therapeutics
LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit www.VIZZ.com and www.LENZ-tx.com.

Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com

Nasdaq closes reporting deficiency following filing of second-quarter 2026 Form 10-Q

FLORHAM PARK, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced that it received written confirmation from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) that Celularity has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission.

Nasdaq’s determination follows Celularity’s October 20, 2026 filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2026. Nasdaq confirmed that the reporting deficiency matter is now closed.

As previously disclosed, on September 11, 2026, Nasdaq confirmed that Celularity had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2), closing both matters. With today’s notification, each of these three previously disclosed deficiency matters has been closed.

“We have repeatedly fallen short of our obligation to provide timely financial reporting, and I take responsibility for that,” said Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer of Celularity. “Our shareholders deserve better. With our filings now current, we must address the recurring delays. We have begun a process to overhaul our finance organization and establish the reporting discipline expected of a public company.”

“The need to strengthen the finance organization was clear when I invested in Celularity, and the late filings did not change my conviction in Celularity’s science and commercial potential,” said Philip A. Barach, a recently appointed director and investor in Celularity. “The Board is working with Dr. Hariri to identify experienced finance professionals who can carry that work forward. Our focus is on building a team that can consistently meet ongoing financial reporting obligations as we aggressively pursue the opportunities ahead.”

About Celularity

Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity draws on the placenta’s unique biology, immunologic properties and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease. Its cellular therapy portfolio includes cenplacel-L, its investigational placenta-derived allogeneic cell therapy, and other investigational cellular therapies. Celularity is headquartered in Florham Park, New Jersey, where it operates a purpose-built cGMP research and manufacturing facility supporting the development and manufacture of cellular therapies, advanced biomaterials and other longevity and wellness-focused products.

For more information, visit www.celularity.com.

Forward-Looking Statements

This release contains forward-looking statements under applicable federal securities laws, including statements concerning Celularity’s finance organization overhaul, expected improvements in financial reporting, ability to maintain compliance with Nasdaq listing requirements, and execution of its regenerative longevity strategy. These statements reflect management’s current expectations and involve risks and uncertainties that could cause actual results to differ materially. Such risks include Celularity’s ability to implement organizational and reporting improvements, maintain sufficient resources to meet its reporting obligations, and satisfy continued listing requirements, together with other risks described in Celularity’s SEC filings. Celularity undertakes no obligation to update these statements except as required by law.

Contact

info@celularity.com

The non-dilutive $16 million capital investment from a third party for Atlas Complex construction advances Callan JMB’s pharmaceutical manufacturing strategy and strengthens its role in U.S. healthcare supply-chain preparedness

SPRING BRANCH, Texas, Oct. 22, 2026 (GLOBE NEWSWIRE) — Callan JMB Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), a diversified preparedness, logistics, and critical-infrastructure company, today is providing shareholders with a timeline to break ground on an intravenous (IV) bag manufacturing and distribution facility at the Atlas Complex in Marion, Alabama. The $16 million facility will be fully funded by a third party through a non-dilutive, non-interest-bearing partnership.

The Company recently announced formal approval of blueprints for the construction and expects to break ground before the end of October. Once the construction is complete and the facility becomes fully operational, it is projected to generate $450 million in annual revenue, including $300 million from standard IV bags and $150 million from premixed drug IV bags.

The facility is planned within the Marion 9 Biomanufacturing Center at the Atlas Complex and demonstrates Callan JMB’s previously announced pharmaceutical manufacturing initiative with Alabama State University. The blueprint approval significantly advanced the project and provided the design basis to break ground to construct a state-of-the-art facility combining automated production with quality-control and advanced distribution capabilities.

“Achieving blueprint approval was a critical milestone, and we are moving quickly to break ground and begin construction on the facility this month. This facility is backed fully by a third-party investment that will not add debt to Callan JMB’s balance sheet nor is dilutive to Callan JMB shareholders. This project builds on our healthcare logistics and emergency-preparedness experience while supporting the strengthening of the United States (U.S.) domestic pharmaceutical production, enhancing U.S. supply chain resilience, and improving national security through medical preparedness,” said Wayne Williams, Callan JMB’s Chief Executive Officer.

About Callan JMB Inc.

Callan JMB Inc. (NASDAQ: CJMB) is a diversified logistics, preparedness, and critical-infrastructure company supporting healthcare organizations, government agencies, and commercial partners. The Company provides fulfillment, warehousing, cold-chain logistics, monitoring, regulatory compliance, specialty packaging, and emergency-preparedness services designed to protect critical products, strengthen supply chains, and support continuity of operations. Through its businesses and strategic partnerships, Callan JMB is building a broader platform spanning healthcare and pharmaceutical logistics, domestic manufacturing, and critical electrical infrastructure. For more information, visit www.callanjmb.com.

Investor Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
CallanJMB@kcsa.com
212.896.1254

Media Contact
Arian Hopkins
ahopkins@callanjmb.com

About the Atlas Complex by Callan JMB

Atlas Complex by Callan JMB is a pharmaceutical, medical, and logistics campus located in Marion, Alabama. Designed to support U.S. pharmaceutical onshoring and strengthen domestic supply chains, the campus provides scalable infrastructure for pharmaceutical manufacturing, quality assurance and quality control (QA/QC), research collaboration, workforce development, cold chain logistics, and domestic distribution within a single integrated environment.

Atlas Complex Media Contact
Arian Hopkins
ahopkins@callanjmb.com

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by, or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

GERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) — Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the following investor conferences in November:

Stifel 2026 Healthcare Conference – November 10-12, 2026 (New York, NY)
Management will participate in a fireside chat at 3:20 pm ET and host one-on-one meetings with investors on Tuesday, November 10th. Click here to access the live webcast.

20th Annual Canaccord Genuity MedTech, Diagnostics & Digital Health Forum – November 11, 2026 (New York, NY)
Management will present at 10:30 am ET and will host one-on-one meetings with investors on Wednesday, November 11th. Click here to access the live webcast.

Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.

About Senseonics

Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com

GRAPEVINE, Texas, Oct. 22, 2026 (GLOBE NEWSWIRE) — Solo Brands, Inc (OTCQB: SBDS), (“Solo Brands” or the “Company”), an omni-channel platform of beloved brands Solo Stove, Chubbies, Oru Kayak, and ISLE, today announced that it plans to report its fiscal third quarter results on November 12, 2026, before the market opens. In conjunction with the release, the Company has scheduled a conference call for management’s prepared remarks on Solo Brands strategy and financial results that will begin at 9:00 a.m. ET.

Investors and analysts are invited to listen to the call by dialing 1-866-652-5200 (international callers, please dial 1-412-317-6060) at least 10 minutes prior to the start and ask to join the Solo Brands call. A live webcast of the conference call will be available in the investor relations section of the Company’s website, https://investors.solobrands.com.

A recorded replay of the call will be available shortly after the conclusion of the call and will remain available until November 19, 2026. To access the telephone replay, dial 1-855-669-9658 (international callers, please dial 1-412-317-0088). The access code for the replay is 8833822. A replay of the webcast will also be available shortly after the conclusion of the call and will remain available for one year.

About Solo Brands, Inc.

Solo Brands, headquartered in Grapevine, TX, is a leading omnichannel lifestyle brand company. Leveraging e-commerce, strategic retail relationships and physical retail stores, Solo Brands offers innovative products to consumers through four lifestyle brands – Solo Stove, known for firepits, stoves, and accessories; Chubbies, a premium casual apparel and activewear brand; ISLE, maker of inflatable and hard paddle boards and accessories; and Oru Kayak, innovator of origami folding kayaks.

Company Contact:
Mark Anderson, Senior Director of Treasury & Investor Relations
investors@solobrands.com

Investor Relations Contact:
Sandy Martin and Steven Hooser
Three Part Advisors, LLC
214-616-2207 / 214-872-2710

Source: Solo Brands, Inc.

Fusion Fuel to Issue 500,000 of its Nasdaq-Listed Class A Ordinary Shares to the Al Shola Gas Minority Shareholders, Subject to Closing Conditions, to Satisfy $2.0 Million of QIND’s Purchase Price, in Exchange for $2.0 Million of QIND Common Stock

Restructuring Removes QIND’s Debt Financing, Credit Facility, Equity Line and Bank Guarantee Commitments, Introduces Quarterly Dividends from Al Shola Gas and Grants QIND an Option to Acquire Al Shola Gas Individual Shareholders’ 49% Ownership Interest

San Francisco, CA, Oct. 22, 2026 (GLOBE NEWSWIRE) — Quality Industrial Corp. (OTCID: QIND) (“QIND” or the “Company”), an industrial energy company specializing in liquefied petroleum gas (“LPG”) infrastructure and distribution, today announced that it has entered into an Agreement and Amendment No. 2 to the Share Purchase Agreement, dated as of September 23, 2026 (the “Amendment”), with Al Shola Al Modea Gas Distribution L.L.C. (“Al Shola Gas”) and the three individual shareholders of Al Shola Gas who together hold 49% of Al Shola Gas (the “ASG Shareholders”). The Amendment amends the Share Purchase Agreement dated March 27, 2024, under which QIND acquired 153 of the 300 shares, or 51%, of Al Shola Gas, as previously amended on April 8, 2025 (together, the “SPA”).

Concurrently with the Amendment, QIND entered into a Share Exchange Agreement, dated as of September 23, 2026 (the “Share Exchange Agreement”), with its majority shareholder, Fusion Fuel Green PLC (Nasdaq: HTOO) (“Fusion Fuel”). Under that agreement, and subject to its closing conditions, Fusion Fuel will issue an aggregate of 500,000 of its Class A Ordinary Shares (calculated by dividing $2.0 million by a price per share of $4.00, subject to adjustment for any share consolidation, share split, share dividend or similar event) to the ASG Shareholders, which issuance will satisfy $2.0 million of QIND’s remaining purchase price under the Amendment, and QIND will issue $2.0 million of its common stock to Fusion Fuel as consideration.

Fusion Fuel’s Role in Satisfying $2.0 Million of the Purchase Price

Under the Amendment, $2.0 million of the purchase price is to be satisfied by the issuance of Fusion Fuel’s Class A Ordinary Shares to the ASG Shareholders pursuant to the Share Exchange Agreement, and that portion will not be deemed paid unless and until the shares are actually issued or the Alternative Payment described below is made. Fusion Fuel’s Class A Ordinary Shares are listed on The Nasdaq Stock Market LLC (“Nasdaq”). Fusion Fuel is not a party to the SPA or the Amendment.

As consideration, QIND will issue to Fusion Fuel shares of its common stock with an aggregate value of $2.0 million. The number of shares will be $2.0 million divided by the lower of (i) the closing price of QIND’s common stock immediately preceding the closing date and (ii) the average closing price for the five trading days ending on the trading day immediately preceding the closing date, rounded to the nearest whole share. If the closing under the Share Exchange Agreement occurs, the issuance of the Fusion Fuel shares will satisfy this $2.0 million portion of the purchase price.

Carsten Kjems Falk, Chief Executive Officer and Interim Chief Financial Officer of QIND, commented: “This is a milestone for QIND. The Amendment provides for quarterly dividend distributions from Al Shola Gas commencing from the third quarter of 2026, unless otherwise determined by the Al Shola Gas Board of Directors, which we believe could provide for cash generated by Al Shola Gas to be used by QIND for payment of its obligations and other working capital and general corporate purposes.”

“Under the amended terms, $2.0 million of the purchase price will be satisfied through Fusion Fuel’s issuance of its Nasdaq-listed shares to the Al Shola Gas shareholders, and QIND will issue its own shares to Fusion Fuel in exchange, which we believe further aligns our two companies. Together with the removal of the legacy financing commitments, the 2027 payment schedule, quarterly dividends from Al Shola Gas and our option over the 49% ownership of Al Shola Gas held by the ASG Shareholders, we believe this restructuring puts QIND’s ownership of Al Shola Gas on a firmer footing and resolves any actual or alleged prior defaults under the SPA through the mutual waiver and release.”

Restructured Purchase Price

The total purchase price for QIND’s 51% interest in Al Shola Gas remains $10.0 million. Following the restructuring, and assuming the $2.0 million portion is satisfied through the closing under the Share Exchange Agreement or the Alternative Payment, $6.98 million remains payable on or before December 31, 2027.

Component   Amount     Form of payment   Timing
Previously paid   $ 1,020,000     Cash   Received by the ASG Shareholders
Fusion Fuel shares   $ 2,000,000     500,000 Fusion Fuel Class A Ordinary Shares at $4.00 per share (subject to adjustment), or the Alternative Payment if the closing under the Share Exchange Agreement has not occurred by December 31, 2026   At closing of the Share Exchange Agreement
2027 payment   $ 6,000,000     Any form determined by QIND in its sole discretion, including cash or securities of QIND, its affiliates or any other person, provided any securities are listed on a securities exchange when delivered   On or before December 31, 2027
Cash payment   $ 980,000     Cash   On or before December 31, 2027
Total   $ 10,000,000          

All purchase price payments are allocated 40% / 40% / 20% among the ASG Shareholders, as above. QIND’s obligation to make the $2.0 million, $6.0 million and $980,000 payments is conditioned on (i) the ASG Shareholders having complied in all material respects with their cooperation obligations for the Share Exchange Agreement closing, and (ii) either that closing having occurred or QIND having made the Alternative Payment.

Additional Terms Benefiting QIND

  • Removal of financing commitments. QIND’s former obligations to provide or arrange debt financing, credit facilities, equity lines, credit lines or bank guarantees for the benefit of Al Shola Gas or the ASG Shareholders are of no further force or effect.
  • Narrowed working capital obligation. The prior working capital provisions are replaced by an obligation to use commercially reasonable efforts to facilitate Al Shola Gas’s purchase of one additional LPG bobtail vehicle of approximately 18,000 liters by December 31, 2026. Al Shola Gas selects the vendor and provides all funds. QIND has no obligation to finance, advance or guarantee any amount.
  • Waiver, release and full satisfaction. The parties mutually waive and release claims relating to any actual or alleged prior defaults under the SPA, including on the timing, amount or form of purchase price payments, the working capital and vehicle obligations, and the debt financing obligations. The ASG Shareholders acknowledge that the restructured purchase price, including the issuance of the Fusion Fuel shares or, if applicable, the Alternative Payment, the revised payment schedule and the deletion of the financing obligations, collectively constitute full and complete satisfaction of all of QIND’s obligations under the SPA arising before the date of the Amendment.
  • Quarterly dividends. Al Shola Gas will make quarterly dividend distributions equal in aggregate to its Profits (as defined in the Amendment) for the previous fiscal quarter, pro rata to equity interests, starting from the third quarter of 2026, unless its Board of Directors determines otherwise. QIND’s pro rata share corresponds to its 51% interest.
  • Call option on the 49% held by the ASG Shareholders. Each ASG Shareholder grants QIND an irrevocable option, exercisable at QIND’s sole discretion on or before March 27, 2027, to buy all or any portion of their Al Shola Gas shares at $65,359.48 per share. That price matches the original $10.0 million valuation for 51%; for all 147 remaining shares it equals approximately $9.61 million. Payment may be made in any form permitted for the purchase price.
  • Right of first refusal. QIND has a 30-day right of first refusal, on the same terms, over any proposed transfer of Al Shola Gas shares by an ASG Shareholder to a third party.
  • Longer restrictive covenants. The period of the ASG Shareholders’ confidentiality, non-competition and non-solicitation restrictions under Section 7.01 of the SPA is extended from two years to four years.
  • Cost sharing. From the third quarter of 2026, the Al Shola Gas Board of Directors may determine that certain costs paid by QIND for Al Shola Gas, including audit fees and administrative expenses, will be shared between Al Shola Gas and QIND.
  • Transfer restrictions controlled by QIND. The Fusion Fuel shares and any other securities delivered to the ASG Shareholders as purchase price are subject to a six-month lock-up, during which they may not be transferred without QIND’s prior written consent. A leak-out then limits each ASG Shareholder’s sales on any trading day to 3% of that day’s total trading volume. Fusion Fuel has agreed to file a registration statement covering the resale of the Fusion Fuel shares no later than 30 calendar days following closing; the filing or effectiveness of the registration statement will not affect the lock-up and leak-out restrictions.

QIND and Fusion Fuel have also mutually waived and released claims arising from their entry into and performance of these agreements, including under the Stock Purchase Agreement dated November 18, 2024 among QIND, Fusion Fuel, Ilustrato Pictures International Inc. and other sellers, solely with respect to these transactions.

Closing Conditions and Alternative Payment

Closing of the Share Exchange Agreement is subject to conditions that, except for a limited ability to waive the accuracy of representations and warranties, the parties cannot waive. These include Nasdaq’s approval of an initial listing application in connection with the transactions contemplated by the November 18, 2024 Stock Purchase Agreement and the issuance of the Fusion Fuel shares, and receipt of all required governmental approvals, including any Nasdaq approvals and any approvals required under the Irish Takeover Panel Act 1997, Takeover Rules. QIND must also deliver accredited investor questionnaires and AML/KYC documentation for each ASG Shareholder. Fusion Fuel is not required to submit or pursue an initial listing application with Nasdaq unless it determines, in its sole discretion, that it will meet the applicable listing requirements at the time.

If the Fusion Fuel shares have not been issued on or before December 31, 2026 because the closing unde the Share Exchange Agreement has not occurred, QIND must, within ten calendar days thereafter, satisfy the $2.0 million portion by paying $2.0 million in cash or delivering other exchange-listed securities valued at $2.0 million in accordance with the Amendment (the “Alternative Payment”).

The foregoing summary is qualified in its entirety by the full text of the Amendment and the Share Exchange Agreement, which QIND has filed as exhibits to a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (the “SEC”) on September 25, 2026.

About Quality Industrial Corp.

Quality Industrial Corp. (OTCID: QIND) is an industrial energy company specializing in LPG infrastructure and distribution and a majority-owned subsidiary of Fusion Fuel Green PLC. Through its majority-owned subsidiary, Al Shola Gas, QIND provides consulting, engineering, installation, maintenance and LPG supply services to residential, commercial and industrial customers across the United Arab Emirates.

About Fusion Fuel Green PLC

Fusion Fuel Green PLC (Nasdaq: HTOO) is a diversified energy platform offering a comprehensive suite of energy supply, distribution, and engineering and advisory solutions through its operating businesses Al Shola Gas, Bright Hydrogen Solutions Ltd (“BrightHy Solutions”) and Biosteam Energy (Proprietary) Limited (“BioSteam Energy”). Al Shola Gas provides full-service industrial LPG solutions, including the design, supply, and maintenance of LPG systems, as well as the transport and distribution of LPG across commercial, industrial, and residential sectors. BrightHy Solutions, the Company’s hydrogen solutions platform, delivers engineering and advisory services enabling decarbonization across hard-to-abate industries. BioSteam Energy provides biomass-powered industrial steam solutions to clients. Through Royal Uranium Inc., the Company also holds a portfolio of uranium and natural gas royalty and other interests across Canada, Colombia and Argentina. For more information, please visit www.fusion-fuel.eu.

Forward-Looking Statements

This press release contains forward-looking statements, which involve risks and uncertainties. Forward-looking statements generally relate to future events or QIND’s future financial or operating performance and can be identified by words such as “may,” “will,” “believes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “should,” “seeks,” “future,” “continue,” “plan,” “target,” “predict,” “potential,” or the negative of such terms, or other comparable terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding: the anticipated issuance of 500,000 Fusion Fuel Class A Ordinary Shares to the ASG Shareholders and of QIND common stock to Fusion Fuel, and the timing of the closing under the Share Exchange Agreement; the satisfaction of the closing conditions under the Share Exchange Agreement; the expected reduction of QIND’s remaining purchase price obligations; the payment of the remaining purchase price on or before December 31, 2027 and any Alternative Payment; the anticipated quarterly dividend distributions by Al Shola Gas and the use of cash generated by Al Shola Gas; any exercise of the call option or right of first refusal; any cost sharing between Al Shola Gas and QIND; QIND’s facilitation of the purchase of an additional LPG bobtail vehicle by Al Shola Gas; the anticipated filing and effectiveness of a resale registration statement by Fusion Fuel; and the expected benefits of the transactions to QIND, including the alignment of QIND and Fusion Fuel and the strengthening of QIND’s ownership of Al Shola Gas. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

These forward-looking statements are based on current expectations and assumptions and are not guarantees of future performance, conditions, or results. They involve known and unknown risks, uncertainties, and other important factors, many of which are outside QIND’s control, that could cause actual results to differ materially from those expressed or implied, including, without limitation: the risk that the closing conditions under the Share Exchange Agreement, including Nasdaq approval of an initial listing application (which Fusion Fuel is not required to submit unless it determines that it will meet the applicable Nasdaq listing requirements) and any approvals required under the Irish Takeover Panel Act 1997, Takeover Rules, are not satisfied in a timely manner or at all; the risk that QIND is unable to issue the required number of shares of its common stock at closing; QIND’s ability to make the Alternative Payment within ten calendar days after December 31, 2026 if the closing under the Share Exchange Agreement has not occurred; QIND’s ability to pay the remaining $6.98 million on or before December 31, 2027; dilution to QIND’s stockholders from the issuance of common stock to Fusion Fuel at the lower of the prior closing price and the five-day average closing price; QIND’s ability to fund any exercise of the call option; the material uncertainty regarding QIND’s ability to continue as a going concern, including QIND’s matured and unpaid convertible notes and its dependence on external financing, including from Fusion Fuel; the risk that Al Shola Gas does not generate Profits sufficient to support dividend distributions, or that its Board of Directors determines not to make them; the risk that the bobtail vehicle purchase is not completed; the risk that the resale registration statement is not filed or declared effective within the required timeframes; geopolitical instability or armed conflict in the Middle East, including disruptions to shipping through the Strait of Hormuz and the departure of customers from the region, that could disrupt Al Shola Gas’s operations, sales volumes, supply chain and costs in the United Arab Emirates; fluctuations in LPG and other energy commodity prices; foreign currency fluctuations; and the risks and uncertainties described in QIND’s Annual Report on Form 10-K filed with the SEC on March 31, 2026, and its other filings with the SEC. Actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. All forward-looking statements in this press release are qualified in their entirety by the cautionary statements above. QIND does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances that may arise after the date hereof, except as required by law.

Contact

Quality Industrial Corp. 505 Montgomery Street, San Francisco, CA 94111 Phone: +1-800-706-0806 Email: info@qualityindustrialcorp.com Investor Relations Website: qualityindustrialcorp.com X: @QualityIndCorp | @Fusion_Fuel

Source: Quality Industrial Corp.

MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will attend and present at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, happening November 16-19 in Boston, MA.

Presentation details:

  1. Title: “Restoring proteostasis in Alzheimer’s disease with buntanetap, a small-molecule translational inhibitor of neurotoxic proteins”
     
    • Presenter: Alexander Morin, PhD, Director, Strategic Communications
    • Type: Oral communications
    • Section: Biotech Showcase 7
    • Date & time: November 19, 3:52 p.m. ET

  2. Title: “Clinical trial design and baseline characteristics of buntanetap’s pivotal study in treating early Alzheimer’s patients”
    • Presenter: Cheng Fang, PhD, Chief Scientific Officer
    • Type: Poster presentation (P025)
    • Section: Clinical Trials – Phase IIB & III
    • Poster display: November 16, 2:00 p.m. – November 17, 5:30 p.m. ET

  3. Title: “Predicting blood–brain barrier permeability of late-stage small-molecule drug candidates for Alzheimer’s disease using artificial intelligence”
    • Presenter: Alexander Morin, PhD, Director, Strategic Communications
    • Type: Poster presentation (P121)
    • Section: AI-Driven Innovation in Alzheimer’s Therapeutics
    • Poster display: November 16, 2:00 p.m. – November 17, 5:30 p.m. ET

“Three presentations at CTAD are a testament to our team’s work advancing buntanetap and pushing the Alzheimer’s field forward,” said Maria Maccecchini, PhD, Founder, President and CEO of Annovis. “Our presentations will cover buntanetap’s innovative mechanism of action, our use of AI for evaluating the Alzheimer’s treatment pipeline, and the updates on our pivotal Phase 3 study in early AD. Together, they reflect our progress as we approach a pivotal data readout in early 2027 and prepare for a New Drug Application. We look forward to sharing all this work and connecting with the Alzheimer’s research community.”

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company’s lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

AUSTIN, Texas, Oct. 22, 2026 (GLOBE NEWSWIRE) — YETI Holdings, Inc. (“YETI”) (NYSE: YETI) today announced that it plans to report its third quarter fiscal year 2026 financial results on Thursday, November 12, 2026, before the market opens. YETI will host a conference call at 8:00 a.m. ET to discuss its financial results.

Investors and analysts who wish to participate in the call are invited to dial 800-717-1738 (international callers, please dial 646-307-1865) approximately 10 minutes prior to the start of the call. A live webcast of the conference call will also be available in the investor relations section of YETI’s website, www.investors.yeti.com.

A recorded replay of the call will be available shortly after the conclusion of the call and remain available until November 26, 2026. To access the telephone replay, dial 844-512-2921 (international callers, please dial 412-317-6671). The access code for the replay is 1186698. A replay of the webcast will also be available within two hours of the conclusion of the call and will remain available on the website for 90 days.

About YETI Holdings, Inc.

Headquartered in Austin, Texas, YETI is a global designer, retailer, and distributor of innovative outdoor products. From coolers and drinkware to bags and apparel, YETI products are built to meet the unique and varying needs of diverse outdoor pursuits, whether in the remote wilderness, at the beach, or anywhere life takes you. By consistently delivering high-performing, exceptional products, we have built a strong following of brand loyalists throughout the world, ranging from serious outdoor enthusiasts to individuals who simply value products of uncompromising quality and design. We have an unwavering commitment to outdoor and recreation communities, and we are relentless in our pursuit of building superior products for people to confidently enjoy life outdoors and beyond. For more information, please visit www.YETI.com.

Investor Relations Contact:
Arvind Bhatia, CFA
Investor.relations@yeti.com

Media Contact:
YETI Holdings, Inc. Media Hotline
Media@yeti.com

CHINO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — Karat Packaging Inc. (“Karat” or the “Company”) (Nasdaq: KRT), a specialty distributor and manufacturer of environmentally friendly, disposable foodservice products and related items, today announced it will release its 2026 third quarter after market close on Thursday, November 5, 2026. The Company will host an investor conference call on the same day.

Call Date: Thursday, November 5, 2026
Time: 2:00 p.m. PT/5:00 p.m. ET
Phone: (800) 715-9871 (domestic); (646) 307-1963 (international)
Conference ID: Karat Packaging Inc.
Webcast: Accessible at https://irkarat.com/events-presentations/; archive available for approximately one year
   

About Karat Packaging Inc.
Karat Packaging Inc. is a specialty distributor and manufacturer of a wide range of disposable foodservice products and related items, primarily used by national and regional restaurants and in foodservice settings throughout the United States. Its products include food and take-out containers, bags, tableware, cups, lids, cutlery, straws, specialty beverage ingredients, equipment, gloves and other products. The Company’s eco-friendly Karat Earth® line offers quality, sustainably focused products that are made from renewable resources. Karat Packaging also offers customized solutions, including new product development and design, printing, and logistics services. To learn more about Karat Packaging, please visit the Company’s website at www.karatpackaging.com.

Investor Relations and Media Contacts:
PondelWilkinson Inc.
Judy Lin or Roger Pondel
310-279-5980
IR@karatpackaging.com

DALLAS, Oct. 22, 2026 (GLOBE NEWSWIRE) — Westwood Holdings Group, Inc. (NYSE:WHG) will release its third quarter 2026 earnings after the close of the New York Stock Exchange on Thursday, November 5, 2026. Following the release, the Company will host a live audio webcast and conference call at 4:30 pm Eastern Time (3:30 pm Central Time).

To join the conference call, please register here: https://register-conf.media-server.com/register/BI60c545b809b742e49e56e3d2ba117f9f. After registering, you will be provided with a dial-in number containing a personalized PIN.

To view the webcast, please register here: https://edge.media-server.com/mmc/p/ka62hjh7. Once registered, an email will be sent with important details for this conference call, as well as a unique Registrant ID.

Date: November 5, 2026

Time: 4:30 PM ET

Listen via Internet: westwoodgroup.com/investor-relations/events-webcasts

Westwood Holdings Group (NYSE: WHG) is a boutique asset management firm that offers a diverse array of actively-managed and outcome-oriented investment strategies, along with white-glove trust and wealth services, to institutional, intermediary and private wealth clients. For over 40 years, Westwood’s client-first approach has fostered strong, long-term client relationships due to our unwavering commitment to delivering bespoke investment strategies with a vehicle-optimized approach, exceptional counsel and unparalleled client service. Our flexible and agile approach to investing allows us to adapt to constantly changing markets, while continually seeking innovative strategies that meet our investors’ short and long-term needs.

Our team at Westwood comes from varied backgrounds and life experiences, which reflects our origins as a woman-founded firm. We are committed to incorporating diverse insights and knowledge into all aspects of our services and solutions. Our culture and approach to our business reflect our core values – integrity, reliability, responsiveness, adaptability, teamwork and driving results – and underpin our constant pursuit of excellence.

For more information on Westwood, please visit westwoodgroup.com.

(WHG-G)


CONTACT: CONTACT: Westwood Holdings Group, Inc.

Terry Forbes

(214) 756-6900

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.